Please select the option that best describes you:
How would you approach a patient whose stage II TNBC tumor is visibly progressing on the KN-522 neoadjuvant regimen?
Currently on C2 of doxorubicin/cylophosphomide/pembro. Would you expedite surgery?
Answer from: Medical Oncologist at Academic Institution
Yes, in a patient whose TNBC is visibly progressing on neoadjuvant chemotherapy, I would change course by either changing regimen or proceeding with local management. The CR rate to the KEYNOTE 522 regimen is impressive (64.8% with pembo vs 51.2% without pembro; Schmid et al., PMID 32101663), but th...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Continue Pembrolizumab after local therapy:- KEYNOTE-522.